Patrick Treanor - 26 May 2022 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Director
Signature
Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
26 May 2022
Net transactions value
$0
Form type
4
Filing time
27 May 2022, 16:18:53 UTC
Next filing
28 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Stock Option (right to buy) Award $0 +17,000 $0.000000 17,000 26 May 2022 Common Stock 17,000 $8.60 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests over a 36 month period: 1/36th on June 26, 2022, after which 1/36th of the total shares vest monthly, subject to the Reporting Person's continued service through each vesting date.